Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New Targeted Therapy for Treatment of Resistant Colorectal Cancer

23.07.2004


The drug cetuximab, a promising new targeted therapy better known as Erbitux, offers another option for patients who have colorectal cancer that resists standard chemotherapy treatment, according to an editorial written by two Mayo Clinic cancer researchers that will be published in the July 22 edition of the New England Journal of Medicine (NEJM).



The editorial is co-authored by Mayo Clinic’s Charles Erlichman, M.D., chair of the Department of Oncology and a specialist in the research and treatment of colorectal cancer, and Daniel Sargent, Ph.D., director of Cancer Center Statistics.

The editorial comments on a phase 2 randomized, three-year study that compared cetuximab combined with irinotecan, a standard chemotherapy regimen, to cetuximab alone in patients with metastatic colorectal cancer that is resistant to treatment with irinotecan. The study was led by David Cunningham, M.D., Royal Marsden Hospital, London and Surrey, in the United Kingdom, and its results will be published in the same issue of NEJM.


Dr. Erlichman notes that although the study indicated the benefits of cetuximab were modest in terms of stopping the cancer, patients’ response to the drug, and survival, it is nonetheless a step forward in the treatment of colorectal cancer that has spread to other parts of the body.

"Cetuximab combined with irinotecan offers patients with metastatic colorectal cancer another treatment option after failing treatment with irinotecan," he says.

About 150,000 people in the U.S. will be diagnosed with colorectal cancer this year, and more than 57,000 will die from it. Colorectal cancer is the second most common cancer in this country, accounting for about 10 percent of annual cancer deaths.

Irinotecan is a chemotherapy drug that is used alone or combined with two other chemotherapy drugs, fluorouracil and leucovorin, for treatment of patients with colorectal cancer. Oxaliplatin is another approved chemotherapy regimen that can be used in combination with fluorouracil and leucovorin as first-line treatment for colorectal cancer, or in patients who have failed irinotecan.

Cetuximab belongs to a new class of cancer drugs called targeted therapies, so named because the drugs go after the source of the cancer and leave healthy cells alone. Cetuximab’s purpose is to disable the epidermal growth factor receptor (EGFR), and thereby prevent cancer cell growth and decrease the ability of cancer cells to overcome the killing effect of chemotherapy.

In laboratory studies, cetuximab had been shown to enhance irinotecan’s antitumor abilities. The study to be reported in NEJM intended to determine whether adding cetuximab to irinotecan can resensitize tumors that are resistant to irinotecan. It found that cetuximab can decrease resistance to irinotecan.

However, Dr. Erlichman notes, there was insufficient evidence to prove that cetuximab improved patients’ survival. Additionally, he disagrees with the study author’s claim that cetuximab compares favorably to oxaliplatin therapy in patients whose colorectal cancer is resistant to irinotecan. He says the effectiveness of oxaliplatin therapy has been established in a large randomized phase 3 clinical study, while cetuximab has not been subjected to such validation.

He describes the results of this study as "the first step in defining the role of EGFR antibody targeted therapy in patients with colorectal cancer."

| newswise
Further information:
http://www.mayo.edu

More articles from Health and Medicine:

nachricht GLUT5 fluorescent probe fingerprints cancer cells
20.04.2018 | Michigan Technological University

nachricht Scientists re-create brain neurons to study obesity and personalize treatment
20.04.2018 | Cedars-Sinai Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Spider silk key to new bone-fixing composite

University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.

Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.

Im Focus: Writing and deleting magnets with lasers

Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...

Im Focus: Gamma-ray flashes from plasma filaments

Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.

The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...

Im Focus: Basel researchers succeed in cultivating cartilage from stem cells

Stable joint cartilage can be produced from adult stem cells originating from bone marrow. This is made possible by inducing specific molecular processes occurring during embryonic cartilage formation, as researchers from the University and University Hospital of Basel report in the scientific journal PNAS.

Certain mesenchymal stem/stromal cells from the bone marrow of adults are considered extremely promising for skeletal tissue regeneration. These adult stem...

Im Focus: Like a wedge in a hinge

Researchers lay groundwork to tailor drugs for new targets in cancer therapy

In the fight against cancer, scientists are developing new drugs to hit tumor cells at so far unused weak points. Such a “sore spot” is the protein complex...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

IWOLIA: A conference bringing together German Industrie 4.0 and French Industrie du Futur

09.04.2018 | Event News

 
Latest News

Magnetic nano-imaging on a table top

20.04.2018 | Physics and Astronomy

Start of work for the world's largest electric truck

20.04.2018 | Interdisciplinary Research

Atoms may hum a tune from grand cosmic symphony

20.04.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>